Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

resmetirom

REZDIFFRA

resmetirom (REZDIFFRA) is a thyroid hormone receptor beta-1 agonist. Associated with Madrigal Pharmaceuticals EU Limited. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Alimentary tract and metabolism (A05) A05
US status approved
Patents linked 10
Pipeline programs 5
News articles 0
Drug details — resmetirom
US status
approved
Class
Alimentary tract and metabolism (A05)
Route
ORAL
Patents
10
Programs
5
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

resmetirom (REZDIFFRA) is a thyroid hormone receptor beta-1 agonist. Associated with Madrigal Pharmaceuticals EU Limited. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN resmetirom
Brand REZDIFFRA
Mechanism Thyroid hormone receptor beta-1 agonist
Target Thyroid hormone receptor beta
Therapeutic class Alimentary tract and metabolism (A05)
Route ORAL
Formulation TABLET
ATC code A05
Originator Madrigal Pharmaceuticals EU Limited

Mechanism of action

Thyroid hormone receptor beta-1 agonist

Primary target: Thyroid hormone receptor beta

Approval history

Authority Status Date
FDA approved —
EMA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Resmetirom Phase 3 · Madrigal Pharmaceuticals EU · NASH
  2. Resmetirom Phase 3 · Madrigal Pharmaceuticals EU · Non-Alcoholic Fatty Liver Disease
  3. MGL-3196 (resmetirom) Phase 2 · Madrigal Pharmaceuticals EU · Heterozygous Familial Hypercholesterolemia
  4. Resmetirom Phase 2 · Madrigal Pharmaceuticals EU · MASH - Metabolic Dysfunction-Associated Steatohepatitis
  5. 100 mg Resmetirom Tablet Phase 1 · Madrigal Pharmaceuticals EU · Renal Impairment

Related & competitor drugs

Browse all drugs
  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Related patents

Browse patents Madrigal Pharmaceuticals EU Limited patent hub

  1. US 12377104

    Methods for treating a fatty liver disease

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11986481

    Method of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11806353

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11564926

    Methods of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11090308

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10894050

    Methods of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10376517

    Methods of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9968612

    Method of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9266861

    Method of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 6369127

    Material based on silicon, in particular for dental impression and method for making such material

    Expires Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is resmetirom?

resmetirom (REZDIFFRA) is a thyroid hormone receptor beta-1 agonist. Associated with Madrigal Pharmaceuticals EU Limited. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for resmetirom?

REZDIFFRA is a marketed brand name for resmetirom. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of resmetirom?

resmetirom has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.